Aeovian Pharmaceuticals is focused on restoring cellular metabolic quality control through highly selective inhibition of mTORC1 or CD38. Its lead candidate, AV078, is a first-in-class, CNS-penetrant selective mTORC1 inhibitor engineered to bypass the toxicities seen with non-selective mTOR blockers such as everolimus. Following encouraging Phase 1 data, AV078 is being advanced into a Phase 2 proof-of-concept trial for patients with TSC-related refractory epilepsy, a condition that affects roughly one million people worldwide and remains resistant to therapy in about two-thirds of cases. The company’s wholly owned pipeline aims to expand selective mTORC1 inhibition to additional rare and age-related indications. Proceeds from its recent financing will support the Phase 2 study and further pipeline development. Aeovian operates out of Berkeley, California and remains privately held; no revenue or user metrics were disclosed in the article.

Total raised

$92M

Funding rounds

3

Latest round

Series B

Latest activity

Dec 2025